Drug intelligence / Profile preview

WASF3 siRNA

Development stage
Preclinical
Lead developer
Keck School of Medicine of University of Southern California
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular
01

Overview

WASF3 siRNA is a small interfering RNA designed to silence the expression of the Wiskott-Aldrich syndrome protein family member 3 (WASF3) gene. WASF3 is a critical regulator of the JAK-STAT signaling pathway and cytoskeletal scaffolding, which are essential for cell motility and tumor cell invasion. In glioblastoma (GBM), WASF3 has been identified as a downstream mediator of the long non-coding RNA LINC03045. Research conducted at the Keck School of Medicine of USC has shown that siRNA-mediated knockdown of WASF3 significantly reduces the invasive capacity of various glioma cell lines, including U87, U251, and patient-derived USC02 cells, in both 2D and 3D assays. This suggests that targeting the WASF3 pathway could be a potential therapeutic strategy to combat the aggressive infiltration and recurrence of glioblastoma.

Other names
WASF3 small interfering RNAWASF-3 small interfering RNAWASF 3 small interfering RNAsiRNA-mediated WASF3 knockdown
02

Targets

WASF3 (WAVE3 / WASF3)

Beyond the preview

Go deeper on WASF3 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WASF3 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call